GG
BCTX

Gofen & Glossberg’s Briacell Therapeutics BCTX Stock Holding History

Gofen & Glossberg’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed -$81K – 628
2021
Q3 		$81K Buy
+67
New +$61.6K ﹤0.01% 585

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return

Gofen & Glossberg's BCTX Position: Q4 2021 in Review

Gofen & Glossberg sold out of Briacell Therapeutics (BCTX) in Q4 2021, closing a stake of 67 shares — an estimated $81K sold.

Gofen & Glossberg first reported a position in BCTX in Q3 2021 and held it in 1 quarter. The position peaked at $81K in Q3 2021. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2021.

  • Gofen & Glossberg reported no remaining Briacell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gofen & Glossberg sold 67 Briacell Therapeutics shares in Q4 2021, an estimated $81K.
  • Gofen & Glossberg first reported a position in Briacell Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gofen & Glossberg's Briacell Therapeutics position peaked at $81K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2021.

Based on Gofen & Glossberg's 13F filing for Q4 2021, filed 25 Jan 2022.